Fiberlab Biotech

$FLI TOKEN
WHITEPAPER

Fiberlab, Inc., Fiberlab Biotech, LLC | CannapūrRx

Pharmaceutical-Grade Cannabinoid Therapeutics.
Powered by Fiberlab on the Solana Blockchain.



Table of Contents

01	Executive Summary	03
02	The Problem	04
03	Market Opportunity	05–06
04	The Cannapūr® Solution	07–08
05	The Fiberlab Token Economy	09–10
06	The $FLI Token	11
07	Tokenomics	12–13
08	Use of Proceeds	14
09	ICO Terms	14–15
10	Private Placement Terms	16
11	Financial Highlights	17
12	Roadmap	18
13	Future Regulatory Evolution	19
14	The Team	19
15	The Fiberlab 3C Foundation	20
16	Legal And Compliance	20–21
17	Closing	22

Executive Summary

Fiberlab, Inc. has spent ten years and over $9.4 million building something the cannabis industry has never seen - a pharmaceutical-grade cannabinoid platform producing cannabinoid acid isolates at 99.9%+ purity without CO_2 and without chemical solvents, independently verified on every single batch with economies of scale.

The technology works. During the years 2018 through 2024, the company operated as a mostly white label manufacturer for third-party brands with some retail sales and brand exposure in the greater Los Angeles area through an established but limited network of distributors and dispensaries. The company had limited wholesale product sales in 2025 while it developed its new business plan focused on medical cannabis.

The timing has never been better. In 2026, the U.S. Drug Enforcement Administration (DEA) reclassified medical cannabis from Schedule I to Schedule III under the Controlled Substances Act (21 U.S.C. § 812). This single regulatory change yields three outcomes that directly impact token holders.

- It removes Medical Cananbis businesses from the scope of IRS Code Section 280E thereby eliminating the tax penalty that has crippled the entire industry and restoring normal business expense deductions for medical cannabis companies. (See "Regulatory Shift" section below for a more detailed explanation,)
- It formally acknowledges accepted medical use and opens the pharmaceutical distribution channel for which Fiberlab's products were originally designed.
- It progressively opens interstate commerce and cross-border trade, enabling national and international scale distribution for the first time.

Fiberlab is ready. Two pharmaceutical-grade products (the Cannapūr®Rx Nasal Spray and Cannapūr®Rx Inhaler) are launching nationally in 2026 through licensed medical and also retail dispensaries in markets where retail cannabis sales are legal. Four AI-developed compound formulas have been developed to increase their footprint and become an industry leader in medical/pharmaceutical cannabinoid therapies. European expansion is planned in 2027.

To fund this launch, Fiberlab is raising $1,500,000 through the $FLI Initial Coin Offering (ICO) Generation Event on the Solana blockchain.

The $FLI token gives holders direct access to the Fiberlab ecosystem, like product discounts, annual token rewards, earnings distributions, a quarterly share of platform revenue in USDC, redemption rights, and governance participation. The token's utility grows in direct proportion to Fiberlab's revenue.

The publicly traded cannabis sector today has a market capitalization of over $15 billion across 40+ companies. Not one produces pharmaceutical-grade cannabinoid isolates at commercial scale. Fiberlab does. Token purchasers entering at the ICO stage are doing so before the national product launch, before European expansion, and before Fiberlab's planned public market listing in 2027 or 2028. The window is open. It will not stay open.

KEY HIGHLIGHTS

- FDA-pathway cannabinoid isolates
- Existing commercial infrastructure
- Solana-based token utility
- Monthly recurring revenue model
- Public market trajectory planned
- Expert scientific leadership

OFFERING SUMMARY

Token	$FLI
Token Supply	
Pre-money	24,000,000
ICO	6,000,000
Post-money	30,000,000
ICO Price	$0.25
Blockchain	Solana
Target Raise	$1,500,000

The Problem

73%
of commercial cannabinoid products fail independent purity testing

0.3%
of companies operate with pharmaceutical-grade validation protocols

$4.1B
annual market value lost to substandard products and recalls

The Industry's Quality Crisis

The cannabis industry has a fundamental quality problem. Batch potency is inconsistent. Synthetic cannabinoids are widespread. Physicians cannot prescribe with clinical confidence. Patients cannot dose accurately. Pharmaceutical-grade production at commercial scale does not exist anywhere in the mainstream cannabis market.

The most therapeutically promising compounds in the cannabis plant - THCA, CBDA, CBCA, CBNA, and CBGA - exist in their fragile acid form in the living plant. Every conventional extraction method, including the industry-standard supercritical CO_2 process, destroys these molecules before they ever reach a patient. The industry has optimized for THC and CBD while the cannabinoid acids with the richest therapeutic profiles have been treated as inactive byproducts.

The largest cannabis markets in the United States are under severe financial stress. California, the world's largest legal cannabis market, is struggling with oversupply, illicit market competition, and tax and regulatory structures that have pushed thousands of operators into insolvency. In 2024 and 2025, more cannabis licenses in California went into default than were renewed. This is not simply a market correction. It is the predictable consequence of an industry that never made the transition from concept to sustainable commercial viability to medicine. Recreational cannabis commoditization has no floor. Medical/Pharmaceutical-grade cannabinoid medicine does.



The Regulatory Shift That Changes Everything

The U.S. DEA proposed reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act (21 U.S.C. § 812), on the formal recommendation of the U.S. Department of Health and Human Services. Schedule I classification had designated cannabis as having no accepted medical use, blocking pharmaceutical distribution channels, denying banking access, and subjecting cannabis businesses to IRS Section 280E, which barred ordinary business expense deductions, including salaries, rent, and certain costs of goods sold from gross income. As a result, before this new ruling, companies were taxed on their gross revenues, which made it extremely difficult to make a profit.

Schedule III classification resolves each of these barriers. Cannabis businesses are removed from Section 280E, restoring normal expense deductions and dramatically improving operating economics. This has a positive impact on bottom-line net income. Medical use is now formally recognized, opening the pharmaceutical and patient-driven distribution channels upon which Fiberlab was founded and built to serve. Banking access improves materially. Interstate commerce and cross-border trade pathways are progressively opening.

Fiberlab's entire technology platform, product architecture, and distribution strategy were built for precisely this regulatory environment.

Market Opportunity

California, Fiberlab's established home market since 2018, has an estimated medical patient base of more than one million users and more than 3,600 licensed dispensary locations. Fiberlab has an existing network of distributors, dispensaries, and strategic partners across Southern California, built over eight years of direct market presence.

Florida is Fiberlab's second priority market and is home to the largest medical-only cannabis program in the United States. As of May 2026, Florida's Office of Medical Marijuana Use reports 929,360 active registered patients, 766 licensed dispensary locations, and 438 million milligrams of THC dispensed weekly. Annual retail revenue ranges from $1.65 billion to $2 billion. The Florida medical cannabis market operates under vertical integration laws, meaning that to become a Medical Marijuana Treatment Clinic (MMTC) in Florida, a company must own the entire operation from seed to sale. This is capital-intensive and will require a secondary capital raise for Fiberlab to successfully enter the Florida medical cannabis market.



GLOBAL CANNABINOID THERAPEUTICS MARKET · USD BILLIONS · 2022–2030E

TOTAL ADDRESSABLE MARKET

$28.2B

Projected 2030

PHARMA PREMIUM

4×

Margin premium for pharmaceutical-grade isolates vs. commodity extracts

QUALIFIED BUYERS

340+

Hospital networks and pharma companies actively sourcing pharmaceutical-grade cannabinoids

North America

$14.8B

52% Market Share

↑ 23% CAGR

Europe

$8.4B

30% Market Share

↑ 31% CAGR

Asia-Pacific

$5.0B

18% Market Share

↑ 28% CAGR

Industry Comparisons

The publicly traded cannabis sector represents over $15 billion in aggregate market capitalization. The leading operators are presented below.

Company	Market Cap	Exchange
Curaleaf	$2.86B	USA
Trulieve Cannabis	$2.23B	USA
Green Thumb Industries	$1.90B	USA
Innovative Industrial Properties	$1.74B	USA
Glass House Brands	$1.11B	USA
Cronos Group	$1.04B	Canada
Tilray Brands	$0.62B	Canada
Canopy Growth	$0.46B	Canada

None of these companies produces pharmaceutical-grade cannabinoid acid isolates at scale. The pharmaceutical-grade segment of the cannabis market has no dominant public company. That is the position Fiberlab is built to occupy and the position $FLI token holders are participating in today.

🎯 Only Fiberlab meets all four pharmaceutical readiness criteria.`

📊 Fiberlab captures market share of the monthly recurring revenue streams.

🚀 Fiberlab achieves first-mover advantages in interstate commerce and cross-border trade.

White-label production has been active since 2018 and manufactures on behalf of third-party brands:

- Pharmaceutical-grade isolates
- Activated acidic cannabinoids
- Compound formulations in bulk or packaged form
- Tinctures
- Edibles
- Vape cartridges

For the product launch in Fall 2026, five commercial distribution channels will be active:

- Direct e-commerce
- Independent distributors and agents
- Regional distributors
- Licensed pharmacies
- White-label manufacturing

The Path to a Broader Ecosystem

The $FLI Token is currently focused on the Cannapūr®Rx product line.

Two affiliated brands are scheduled for full commercial launch in 2027:

- **Kannavi™** – an activated CBDA-based skincare line
- **AlphaX™** – a psilocybin-based microdosing brand for sexual health and wellness

Fiberlab holds a majority interest in both companies.
As these brands launch and integrate with the Fiberlab platform, the utility of the $FLI Token will extend across the entire ecosystem and broaden the revenue base supporting token-holder rewards and income.

Brand	Focus	Planned Launch
Cannapūr®Rx	Pharmaceutical Cannabinoid Therapeutics	2026
Kannavi™	Activated CBDA Skincare	2027
AlphaX™	Psilocybin Microdosing for Sexual Health & Wellness	2027

The Solution - Cannapūr® Technology

A Decade of Science, Producing What the Industry Cannot

The fundamental problem with conventional cannabis processing is temperature. The cannabinoid acids with the most promising therapeutic profiles are thermolabile molecules that degrade rapidly under heat, pressure, and chemical exposure. Every standard extraction method exposes biomass to conditions that destroy these compounds before isolation can even be attempted.

Fiberlab built an entirely different process from the ground up. The result is the Cannapūr technology platform, a proprietary closed-loop cryogenic extraction and isolation system that operates at sub-zero temperatures throughout the entire production cycle without CO_2, chemical solvents, or compromise to the molecular integrity of the cannabinoid acids being isolated.

From Plant to Pharmaceutical in Six Stages

STAGE 01

Whole-Plant Sourcing

Certified, third-party ISO certified cannabis biomass selected and optimized for maximum cannabinoid acid content.

STAGE 02

Cryogenic Pre-Treatment

Biomass is extracted while still fresh or flash-frozen immediately after harvest, which locks in the full molecular profile of all five cannabinoid acids.

STAGE 03

Closed-Loop Extraction

Proprietary closed-loop system extracts at precisely controlled sub-zero temperatures with zero CO_2 and zero chemical solvents.

STAGE 04

Proprietary Isolation

Multi-stage cryogenic isolation and patentable finishing technology - each isolate is collected, analyzed, and verified individually.

STAGE 05

Pharmaceutical Verification

Independent ISO-accredited third-party testing on every batch across potency, solvents, heavy metals, microbials, and mycotoxins

STAGE 06

Formulation and Activation

Isolates are activated and remain as stand-alone cannabinoids or are precisely blended into compound formulas for accurate clinical micro-dosing at the milligram level.

Testing Methods: HPLC-UV/LC-MS for potency and identity. GC-MS Headspace for residual solvents. ICP-MS for heavy metals. qPCR and culture for microbial contamination. LC-MS/MS for mycotoxins.

The Five Pharmaceutical-Grade Isolates

Fiberlab has successfully isolated five acid cannabinoids. These five isolates are scaleable and ready for market in micro-dosing or pharma-grade compounding.

Isolate	Full Name	Therapeutic Profile	Primary Applications
THCA	Tetrahydrocannabi nolic Acid	Neuroprotective, anti-inflammatory, anti-nausea, increased appetite	Neurological disorders, chemotherapy-ind uced loss of appetite, inflammation, nausea, and pain
CBDA	Cannabidiolic Acid	Serotonin-modulati ng, anxiolytic	Anxiety, PTSD, treatment-related nausea
CBGA	Cannabigerolic Acid	Metabolic precursor, antibacterial	Metabolic support, foundational compound formulas
CBCA	Cannabichromenic Acid	Neurogenesis, antimicrobial	Neurological protocols, inflammation
CBNA	Cannabinolic Acid	Sedative, appetite-stimulating	Sleep disorders, appetite support, oncology protocols

What Sets Fiberlab Apart

Cryogenic extraction with no CO_2 and no harsh chemical solvents preserves the integrity of the whole plant material, yielding cleaner isolates and a smaller environmental footprint than any conventional competitor. Using less energy and while at the same time maximizing yields and reducing waste makes Fiberlab more efficient and cost-effective than our competitors, resulting in a higher net income margin.

Subzero cryogenic integrity preserves the molecular structure of all five cannabinoid acids throughout extraction, whereas these compounds degrade entirely under conventional extraction temperatures. Full pharmaceutical traceability, from the biomass lot number to the final certificate of analysis, provides physicians and compounding pharmacies with the verification standard they require. Consistent 99.9%+ purity enables accurate microdosing and compounding at the milligram level, which is critical for patients managing neurological conditions, PTSD, oncology symptoms, chemotherapy, arthritis, inflammation, seizures, chronic pain, appetite loss, and others.

"Cannabinoids the Way Nature Intended"

The Fiberlab Token Economy

One Product. One Token. One Clear Purpose.

The $FLI token serves as the utility and access layer for the Cannapūr®Rx product and Fiberlab corporate ecosystem. It is directly tied to the products Fiberlab will launch later this year — the CannapūrRx Cannabinoid Nasal Spray and the Cannapūr®Rx Cannabinoid Inhaler — which are distributed nationally through licensed compounding pharmacies under physician-directed protocols.

Every dollar in CannapūrRx product revenue generated through the Fiberlab platform strengthens the $FLI token ecosystem. As product sales grow, platform activity increases, expanding the utility and reach of the $FLI token across more dispensaries, more products, and more services. Token holders gain broader access to Cannapūr®Rx products at preferential pricing, priority participation in new product launches, and an expanding set of platform features tied directly to ecosystem growth. The $FLI token is not a passive instrument. Its value as an access and participation tool grows in direct proportion to Fiberlab's commercial footprint. The more the platform grows, the more there is to access, use, and engage with as a token holder.

The CannapūrRx Product Line

Both products are manufactured at 99.9%+ pharmaceutical-grade purity, GMP-certified, all-natural, free of artificial additives, and dispensed exclusively through licensed dispensaries and compounding pharmacies under the direction of physicians and caregivers or directly to consumers with a medical cannabis card in medical-only markets and to all consumers in legal markets.

Cannapūr®Rx Cannabinoid Nasal Spray. Advanced nasal delivery for rapid systemic absorption. 10mL per unit, with 100 precision doses of 99.9%+ pure activated THCA (THC) at three percent per dose. No artificial flavors, colors, or preservatives. Manufactured in GMP-certified facilities. For patients requiring fast-onset relief with accurate, repeatable dosing.

Cannapūr®Rx Cannabinoid Inhaler. Pulmonary precision delivery for targeted, fast-acting relief. Our 99.9%+ pharmaceutical-grade cannabinoids are delivered directly to the respiratory system without combustion, solvents, or artificial additives. This is ideal for patients managing acute symptoms, where immediate onset and dose consistency are clinically essential. Fiberlab biomass raw materials and finished products are manufactured in a GMP-certified facility.

How Products Reach Patients

Products are sold or dispensed directly from the company or through licensed dispensaries, distributors, and pharmacies under a four-step physician- or caregiver-directed instruction. The patient consults their physician regarding a Fiberlab cannabinoid protocol. Using the Fiberlab locator on their website, the patient is directed to a licensed dispensary or compounding pharmacy partner in their state and the closest ZIP code.

The Existing Commercial Infrastructure

Fiberlab has operated in California since 2018 with a limited but established network of distributors, dispensary partners, and industry professionals across Southern California. White-label manufacturing has been active since 2018, producing pharmaceutical-grade isolates, activated acid cannabinoids, compound formulations in bulk or packaged, tinctures, edibles and vap cartridges for third-party brands on contract. Five commercial channels will be active for product launch in the fall of 2026: direct e-commerce, independent sales contractors and agents, regional distribution partners, licensed dispensaries, and white-label manufacturing.

The Path to a Broader Ecosystem

The $FLI token is currently focused on the Cannapūr®Rx product line. Two affiliated brands, Kannavi™, an activated CBDA-based skincare line, and AlphaX™, a psilocybin-based micro-dose sexual health and wellness brand, are planned for full commercial launch in 2027. Fiberlab holds a majority equity stake in both companies. As these brands launch and integrate with the Fiberlab platform. The $FLI token's utility will extend across the entire ecosystem, broadening the revenue base that supports token holder rewards, and earnings.

The $FLI Token

The $FLI token is a utility token issued by Fiberlab, Inc. on the Solana blockchain and compliant with the SPL Token-2022 standard. It is the sole means of access to participation in the Fiberlab digital ecosystem, enabling holders to purchase Cannapūr®Rx products at a discount, earn annual token rewards, earnings distributions and participate in platform governance.

Fiberlab selected Solana for three reasons: fast, sub-second transaction confirmation at a fraction of a cent per transaction, immediate liquidity access via the Raydium decentralized exchange at the time of public listing, and the SPL Token-2022 smart contract functionality required to support automated reward distribution and platform operations.

What $FLI Token Holders Receive

Product Access and Discounts. Preferential pricing applies to all Cannapūr®Rx products purchased on the Fiberlab platform. It also extends to Kannavi and AlphaX products from their respective 2027 launch dates. Fiberlab products across the ecosystem can be purchased using $FLI tokens. This increases liquidity through token purchases and reduces the number of tokens in the free float.

Annual Token Holding Rewards.

5% of the held token balance is rewarded annually in $FLI tokens from the pre-allocated ecosystem rewards pool. Holders log in to the Fiberlab portal, complete a brief product feedback form to provide R&D data to Fiberlab. Then, the clients instantly claim their reward to their connected wallet.

Annual Token Holding Earnings

Token holders that maintain ownership of their tokens will receive a 5% $FLI token earnings distribution annually.

Platform Engagement Rewards.

Active token holders who engage with the Fiberlab platform by purchasing products, complete product feedback forms, and participate in governance may earn platform credits based on their level of ecosystem activity. These credits are redeemable against future product purchases on the Fiberlab platform, giving active participants a tangible benefit that grows with their engagement. Platform credits are not guaranteed and are subject to availability and platform performance.

Governance Participation.

Token holders can earn tokens by Voting on ecosystem decisions, such as product development priorities, platform features, and ecosystem partnership proposals.

The Technology Platform

The Fiberlab Technology Platform is developed and built by Debut Infotech on a 12-week schedule. The Platform involves Smart contracts in Anchor and Rust on Solana. The backend is in NestJS with TypeScript, PostgreSQL, Redis, and BullMQ. The Frontend is in ReactJS, and is fully mobile-responsive. The KYC is via Sumsub, and is GDPR compliant. The Fiat on-ramp is via Transak, Ramp Network, and MoonPay. Compatible wallets are: Phantom, Solflare, and Backpack. It is a =bBilingual platform in English and German. The Security is: OWASP Top-10 compliance, SEC3 blockchain audit, and independent penetration testing before launch.

USDC (US Dollar Coin) Redemption. $FLI token holders may redeem their tokens for USDC through the Fiberlab platform. Redemption requests are processed within 72 hours. The redemption facility is funded by platform revenue and ongoing token sales

- USDC stands for US Dollar Coin.
- It is a type of stablecoin pegged to the US dollar.
- USDC is used for digital transactions and trading cryptocurrencies.
- USDC is issued by regulated financial institutions.
- The coin is designed to maintain a 1:1 value with the US dollar.
- USDC is widely used in decentralized finance (DeFi) applications.

Tokenomics

Token Supply

Initial issuance of 6,000,000 tokens at the Initial Coin Offering (ICO) at $0.25 per token as displayed in the financial model. The initial token supply at listing is 30,000,000, with a maximum lifetime supply of 500,000,000 tokens.



Vesting Schedule

Founding and Management Team tokens are restricted for 12 months and then vest in two phases. 20% of the team allocation (2,400,000 tokens) vests at 12 months. The remaining 80% (9,600,000 tokens) vest linearly over 12 months from the initial unlock date. Founding and Management token liquidation is restricted to 10% of the preceding month's total trading volume.

Fiberlab seed-capital tokens vest in two phases. 20% of the seed-capital tokens unlock 90 days after the listing. The remaining 80% vest linearly over 12 months from the 90-day unlock date.

Public ICO tokens: 20% (1,200,000 tokens) are free to trade 90 days after the ICO closes. The remaining 80% (4,800,000 tokens) vest linearly over the subsequent twelve months.

Token Pricing and Valuation

The $FLI tokens pre-money valuation is $0.25 per token, implying a market value of $6,000,000 for the initial issuance of 24,000,000 tokens. The additional 6,000,000 $FLI tokens issued in the ICO create a $7,500,000 post-money valuation. The $ 2.00-per-token listing price creates a $60,000,000 public listing valuation. The $60,000,000 Solana Blockchain valuation is 8x the $7,500,000 post-money valuation.

Cap Table	Tokens	Price per Token	Valuation
Pre-money	24,000,000	$0.25	$6,000,000
ICO Target Raise	6,000,000	$0.25	$1,500,000
Post-money	30,000,000	$0.25	$7,500,000
Solana Blockchain Listing	30,000,000	$2.00	$60,000,000

Valuation Metrics

The post-money valuation for $FLI is based on factors such as market size, intellectual property, product advantages, interstate commerce, cross-border trade, established operating history, developed markets in the U.S. and Europe, proven established distribution channels in the U.S. and Europe, exemption from IRS Code Section 280e, the tax-exempt 3C Foundation with access to endowments and research grants, as well as financial projections and operating profit margins.

What Drives the Token's Value

Platform activity and product revenue growth drive ecosystem demand for the $FLI token. As Fiberlab's commercial footprint expands across more dispensaries, products, and markets, the utility of holding $FLI tokens increases proportionally. The vesting schedule controls supply by staggering token releases over 3 to 18 months. The Raydium liquidity pool ensures buyers and sellers can transact at all times without requiring a matched counterparty.

Use of Proceeds

Use	Amount
Capital Equipment	$497,648
Installation	$40,000
Product Packaging and Fulfillment	$40,000
Debt Repayment	$350,000
Working Capital	$400,000
Offering and Platform Costs	$172,352
Total	**$1,500,000**

ICO Terms

The Opportunity at the Ground Floor

The $FLI TGE offers the earliest public private placement opportunity to participate in the Fiberlab ecosystem before the public listing on the Solana Raydium Exchange. The TGE fundraising target is $1,500,000. The minimum participation threshold is $25,000.

Participants complete the required Know Your Customer (KYC) forms through the Fiberlab investor portal, purchase with fiat via Transak, Ramp Network, or MoonPay, or connect a compatible Solana wallet directly. Upon participation, tokens are issued in accordance with the vesting schedule above.

Investor Benefits Summary

Fiberlab Shareholders Founders Tokens	**Seed capital price at $0.10 per token**
Early Entry Price for Fiberlab Shareholders and Angel Investors	**Entry price in the private placement relative to the $0.25 per token valuation established in the financial model**
Annual Token Rewards	**5% of the held balance annually in $FLI**
Quarterly Revenue Share	**25% of platform fees distributed in USDC**
USDC Redemption	**1:1 at $1.00 per token, within 72 hours**
Platform Engagement Rewards	**Platform credits earned through active ecosystem participation, redeemable against future product purchases**
Product Discounts	**Preferential pricing across CannapūrRx products**
Governance Rights	**Voting on platform and ecosystem decisions**
Fiberlab, Inc. 3-year common stock purchase warrants exercisable at $0.25 per share.	

Monthly Recurring Revenue (MRR)

Unlike the recreational cannabis market, where sales are based solely on a consumer's desire to purchase and consume cannabis products, the medical/pharmaceutical cannabis sectors are patient and physician driven. This creates a monthly user base where patients and consumers Use and are prescribed medical cannabis products every month. Under this MRR model, prices and consumer demand are stable, which allows for more accurate financial modeling and forecasting.

5-Year Projected 5-Year Cash Flow Valuation

Metric	Projection
Investment	**$1,500,000**
Cash Flow Positive	**Q2 2027**
IRR (5-Year)	**56.7%**
NPV	**$3,351,912**
Hurdle Rate	**15%**
Payback Period	**2.48 years**
ROI (5-Year)	**3.69x**

This Cash Flow Valuation does not factor profits from the 6,000,000 $FLI tokens or the shares from the Fiberlab, Inc. common stock warrants.

Private Placement Terms

Structured Access for Qualifying Investors

Fiberlab is offering $FLI tokens to early strategic participants through a structured private placement. Token purchasers participating at this stage are entering before the national product launch, the European expansion, and Fiberlab's planned public market listing in 2027-2028, and on terms that will not be available once the token enters public markets.

Qualifying accredited investors participating in the private placement receive a unit offering consisting of two distinct instruments. The first is the $FLI utility token, which includes all ecosystem benefits described in this whitepaper. The second is a 3-year warrant to purchase Fiberlab, Inc. common stock at $0.25 per share, issued separately under a Private Placement Memorandum and governed by applicable U.S. securities laws.

Fiberlab is targeting a public market listing for its shares between 2027 and 2028. Private placement participants entering today at $0.25 per share via the warrant are positioning themselves ahead of the listing on terms that will not be available once the company's shares are traded on public markets. The gap between today's warrant price and the anticipated public listing valuation represents the equity upside available exclusively to private placement participants at this stage.

To receive the full PPM and warrant terms, contact Edward Klaeger at ejk4@fiberlab.io.

Fiberlab's Public Market Trajectory

Fiberlab's management is targeting a public market listing on a U.S. or Canadian securities market in late 2027 or 2028 with a planned dual listing on the Frankfurt Stock Exchange thereafter. Fiberlab's CEO, Edward Klaeger IV, has direct experience listing companies on U.S. markets, the Frankfurt Stock Exchange, and the London Alternative Investment Market (AIM), and has raised and invested over $200 million in capital during his career. This is a proven track record, not an aspiration.

As Fiberlab matures toward its planned public markets strategy, the company may also evaluate security token offerings or other regulated structures as alternative or complementary pathways. Any such transition will be conducted in full compliance with applicable laws and in consultation with qualified legal and regulatory advisors.

Financial Highlights

A Proven Business Model with a Clear Path to Scale

Fiberlab generated approximately $1,000,000 in revenue with a 24% EBITDA margin in 2020, operating in one of the most hostile regulatory environments in the cannabis industry's history. The business model works. The 2026 relaunch is an acceleration of a platform that has already demonstrated commercial viability.

The five-year pro forma model below is built on the Cannapūr®Rx product launch in 2026, Florida and national expansion through 2027, and European market entry starting in 2027. These 5-Year Projections are achievable if Fiberlab captures less than 1% of the California and Florida medical cannabis markets alone, not including white label revenue or revenue from the European market, Kannavi™ or AlphaX™.

Year	Revenue	Operating Cash Flow	Net Income	EBITDA
2027 (Year 1)	**$705,681**	**$18,307**	**$88,817**	**$112,426**
2028 (Year 2)	**$4,346,894**	**$1,418,021**	**$1,689,334**	**$2,138,398**
2029 (Year 3)	**$11,596,995**	**$4,380,591**	**$4,812,017**	**$6,091,160**
2030 (Year 4)	**$25,133,381**	**$10,054,629**	**$10,886,803**	**$13,780,764**
2031 (Year 5)	**$48,684,763**	**$20,170,962**	**$21,549,466**	**$27,277,805**

Year 1 (2027)

covers the ramp-up period through the Cannapūr®Rx national launch and Florida market entry, culminating in the projected cash-flow-positive milestone in Q2 2027.

Year 2 (2028)

reflects a larger CannapūrRx footprint in the US market and entry into the European market.

Years 3 through 5 (2029 to 2031)

reflect sustained growth in the US and European markets, not including white label revenue or revenue from Kannavi or AlphaX.



Why This Raise at This Moment

The $1,500,000 ICO raise is a calculated amount to bridge Fiberlab from its current pre-launch position to cash-flow-positive operations in Q2 2027 when the business will fund its own growth through product revenue and its public listing. Token purchasers entering at this stage are providing the capital needed to move a proven technology from a single-market model to national commercial distribution in a market transformed by the most significant regulatory reform in cannabis' history

Roadmap

2016 - 2018 (Foundation and Proof of Concept)

- Incorporate Fiberlab in the United States
- Build the first cryogenic extraction prototype
- Achieve 97.2% THCA and CBDA purity at lab scale
- Launch commercial production in California
- Establish the first white label B2B revenue

2019 - 2020 (Commercial Validation)

- Reach 99.9%+ purity across all five isolates at commercial scale
- Generate $1M revenue at 24% EBITDA
- Build California distributor, dispensary and strategic relationship network
- Expand white label manufacturing client base
- Validate demand for pharmaceutical-grade isolates

2021 - 2024 (Strategic Repositioning)

- Continue white label manufacturing
- Increase wholesale footprint
- Scale back California retail sales

2025 - Q2 2026 (Relaunch and ICO)

- Redirect all resources to medical/ pharmaceutical launch
- Position ahead of DEA Schedule III reclassification
- Create CannapūrRx brand
- Develop the CannapūrRx nasal spray and inhaler for national launch
- Launch $FLI Initial Coin Offering Generation Event on Solana
- Initiate CannapūrRx national distribution
- Close first ICO tranche, begin 90-day countdown

Q3 2026 - 2027 (Scale and Ecosystem Growth)

- List $FLI token publicly on Raydium
- Distribute first annual token rewards
- Clinical validation of the four compound formulas
- Achieve cash flow positive milestone in Q2 2027

2027 - 2028 (Expansion and Public Listing)

- Launch CannapūrRx across European markets
- Commercial launch of the four new compound formulas
- Commercially launch Kannavi and AlphaX brands
- Activate full three-brand token ecosystem
- Onboard health and wellness platform partners
- Execute public market listing on a U.S. or Canadian exchange.
- Complete dual listing on the Frankfurt Stock Exchange (FSE)

Future Regulatory Evolution

The $FLI token is initially structured as a utility token to enable participation in the Fiberlab ecosystem and accelerate platform adoption. This approach allows the company to focus on product development, user growth, and ecosystem utility while maintaining a streamlined compliance framework aligned with the current regulatory environment.

The DEA's proposed reclassification of cannabis from Schedule I to Schedule III formally acknowledges its accepted medical use, eliminates the Section 280E tax burden, and opens pharmaceutical distribution channels, interstate commerce, and cross-border trade. Fiberlab's technology platform was designed and built to operate in this exact environment.

As the platform matures, regulatory guidance on digital assets evolves and new business opportunities emerge, Fiberlab may evaluate alternative token structures, including a regulated security token framework. Any such transition would be undertaken in consultation with qualified legal and regulatory advisors and in full compliance with applicable law.

This phased approach provides the flexibility needed for responsible growth while preserving the ability to respond to future market, participant, and regulatory requirements as they arise.

The Team

Edward J. Klaeger IV

Founder, Managing Director, and Chief Executive Officer.

35 years of experience in corporate finance and asset management across U.S. and European capital markets. Worked directly with the IMF, the World Bank, the European Bank for Reconstruction and Development (EBRD), and the Organization for Economic Cooperation and Development (OECD). Served on the Board of Directors of the OECD and the European-Ukrainian Energy Agency (EUEA). He has raised and invested over $200 million in capital and has listed companies on U.S. markets, the Frankfurt Stock Exchange, and the London Alternative Investment Market (AIM). His expertise spans corporate finance, M&A, pre-IPO and IPO structuring, financial modeling, and international market strategy.

Jon Queen

President and Head of Legal

Over 20 years of investment banking, financial, and corporate advisory experience. Juris Doctor from the University of Pennsylvania, MBA from the Kyiv School of Economics, and Bachelor of Science in Economics from Cornell University. Career spans John Hancock Financial Services, Latham and Watkins LLP, commodity trading in Hong Kong for Capital Partners Securities and the Anemone Group, and leadership roles at leading Central European investment banks from 2010 to 2017. One of the most active secondary-market traders of carbon credits globally during the Kyoto Protocol period.

Bryce Meeker

Managing Director, Global Business Development.

Corporate development executive with a track record of leading high-impact venture investments, M&A transactions, sales, and strategic advisory work across multiple industries. Proven business developer with the ability to drive corporate partnerships that mitigate risk, generate revenue, and create strategic growth opportunities. Experienced project manager adept at working in complex regulatory, permitting, and political environments across the U.S. and in emerging markets, and at leading diverse, cross-functional teams. Recognized for strategic vision, entrepreneurship, financial modeling, problem-solving, risk management, contract negotiation, and delivering innovative, sustainable solutions.

Natalie Roseth

Co-Founder, Managing Director, Oncology and Global Sales and Marketing.

Over 20 years of sales account management, business development, and marketing experience, with a focus on the pharmaceutical, biotech, hospital, and medical device industries. Currently active in the oncology sector - with direct experience in the physician and clinical network that CannapūrRx is designed to serve. Demonstrated track record in new market development, large-geography territory management, and enterprise account management across complex business environments.

Samuel M. Kearley

Managing Director, European Sales and Marketing.

Over 10 years of experience in cannabis, nutraceuticals, and wellness-focused consumer goods across European markets. Since 2016, led sales and business development at Reakiro, a European CBD and wellness manufacturer, building commercial 32 | Page DRAFT v.4 compare operations from inception across the UK, EU, and Asia - scaling revenue from zero to multi-million-dollar annual turnover. Established long-term B2B partnerships across wholesale, private label, white label, and contract manufacturing. Co-founded international networking platforms that have organized over 150 events across the EU. Former broadcast journalist for Ukraine Today.

Scientific and Engineering Team

The intellectual property used to create our 99.9%+ pure acid cannabinoid isolates and compound formulas was developed by 3 PhDs and 2 MScs in the fields of biochemistry and chemical engineering. Our proprietary technology was developed by 2 process engineers and one MSc.

The Fiberlab 3C Foundation

Fiberlab, Inc. is the founding sponsor of the Fiberlab Compassionate-use Care and Cancer Foundation, a planned 501(c)(3) nonprofit organization established to ensure that cancer patients and those with chronic ailments and af$FLIctions who cannot afford Fiberlab's pharmaceutical-grade cannabinoid products are not denied access due to financial constraints.

The Foundation is funded through a donations, endowments and grants as well as a fixed percentage of Fiberlab's ecosystem activity each year, creating a direct and permanent link between the platform's commercial success and the Foundation's capacity to serve patients in need. As the ecosystem grows, the Foundation's funding grows proportionately. Contributions are tax-deductible under applicable U.S. law, and the Foundation is eligible for federal grant programs.

The Foundation is not a marketing initiative. It is a planned legal entity already in process, that embodies Fiberlab's founding principle: Make our products affordable to those in financial need and develop new products to help those suffering from disease and af$FLIctions manage their symptoms.

Legal And Compliance

Corporate Structure

Fiberlab, Inc. is incorporated in Nevada, and Fiberlab Biotech, LLC is established in Wyoming, United States. Fiberlab, Inc. has operated continuously since June 2016. Cannapur is a 100% wholly-owned registered tradmark of Fiberlab, Inc. Fiberlab and The Cannabinator are prior owned registered trademarks of Fiberlab, Inc. that are being re-registered. Cannasur is in the regisrattion procees, all of which are 100% owned by Fiberlab, Inc. Fiberlab Biotech, Kannavi, and AlphaX are 100% wholly-owned subsidiaries of Fiberlab, Inc. All intellectual property developed during the company's operational history is retained in full by Fiberlab, Inc.

Token Classification

For ease of listing at a minimal cost and regulatory review the $FLI token is a utility token. It does not represent equity ownership in Fiberlab, Inc., nor does it confer dividend or corporate voting rights or any claim on company assets beyond the specific platform benefits described in this whitepaper. The review by independent legal counsel of the utility token classification has not been formally concluded at the time of publication. Participants are strongly encouraged to seek independent legal, financial, and tax counsel before participating. Fiberlab plans to reclassify $FLI as a Security Token in the future.

KYC and AML

All participants complete identity verification through the $FLI Token Portal via Sumsub, a GDPR-compliant service. Fiberlab reserves the right to decline participation by any individual or entity that does not complete KYC or that poses an Anti-Money Laundering risk.

Jurisdiction

The $FLI token is offered globally with no formally excluded jurisdictions at this time. Participants are responsible for ensuring that their participation is lawful under the laws and regulations of their location's jurisdiction.

Private Placement

Instruments available through the Private Placement Memorandum are offered exclusively to accredited investors under applicable exemptions from U.S. securities registration requirements. Nothing in this whitepaper constitutes an offer to sell securities.

Smart Contract Security

The $FLI token smart contract is subject to an independent security audit by Sec3 prior to deployment, independent penetration testing prior to the public launch, and Open Worldwide Application Security Project “WASP” Top 10 compliance throughout the platform's development.

Risk Factors

Participation involves significant risk. The cannabis regulatory environment remains subject to change, and the Schedule III reclassification has not been formally finalized as of the publication date of this white paper. The digital asset market is volatile and unregulated. The price of $FLI tokens may be substantially lower than the private placement entry price. Financial projections are forward-looking and subject to material uncertainty. Actual results may differ materially. The platform is subject to technology risk, including smart contract vulnerabilities and cybersecurity threats.

"The Convergence of Science, Regulation, and Timing"

The technology is proven. The science is proven. The compound formulas and products are proven. A decade of proprietary research and $9,412,733 in investment through June 30, 2026, have produced a pharmaceutical-grade cannabinoid platform that generates isolates with 99.9%+ purity, without CO_2, chemical solvents, or compromise. The technology exists. The products exist. The production capacity exists.

The regulatory landscape has shifted. The DEA's proposed reclassification of medical cannabis from Schedule I to Schedule III is the most consequential federal regulatory change in cannabis history. The Section 280E tax burden is lifted. The pharmaceutical distribution channel is open. Interstate commerce pathways are clearing. The environment Fiberlab spent a decade preparing for has arrived.

The timing is now. Cannapūr®Rx is launching in California in 2026. Florida is the second target market in 2026, with a national launch in 2027. Europe follows in 2027. A public market listing is targeted for late 2027-2028. The $FLI Token Generation Event is the final entry point before all of this becomes fully public.

Token purchasers, who enter at this stage, participate before the national product launch, European expansion, and public listing, ahead of the broader community gaining access to Fiberlab at any price. The $FLI token serves as a functional utility instrument tied to real product revenue, offering concrete holder benefits, product access, platform engagement rewards, and a governance voice in the platform's future.

Fiberlab has spent ten years building a unique process to produce pharmaceutical-grade cannabis-based products.. The window to participate on these terms is now open.

To participate in the $FLI Initial Coin Offering Generation Event or to request the Private Placement Memorandum, visit the respective landing page.

Website: www.fiberlab.io, www.fiberlabbiotech.com

Email: ejk4@fiberlab.io

General: info@info@fiberlab.io